All In Biotech

Drug Trial Radar · NCT07615179

Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)

Impact of Alirocumab on Cardiovascular Events in Individuals With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

4,545

Actual

Start

Feb 17, 2025

Primary completion

Sep 30, 2025

Study completion May 30, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 29, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate ischemic event rates among individuals with established atherosclerotic cardiovascular disease without prior acute ischemic events, comparing those treated with alirocumab versus those receiving no proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapy. The study will leverage observational data reflective of routine clinical practice and will apply contemporary approaches in target trial emulation and causal inference to estimate treatment effects.

Conditions

  • Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events

Interventions

  • AlirocumabDrug

    The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.

  • Comparator: No PCSK9i Therapy (either mAb or siRNA)Drug

    The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of nonfatal myocardial infarction, nonfatal ischemic stroke, or all-cause mortalityTime frame: From index up to 5 years follow up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sanofi

    Bridgewater, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.